X Ray News and Research

RSS

Hospital executive charged in $1.4B rural hospital billing scheme

A Miami entrepreneur who led a rural hospital empire was charged in an indictment unsealed Monday in what federal prosecutors called a $1.4 billion fraudulent lab-billing scheme.

30 Jun 2020

Essential worker shoulders $1,840 pandemic debt due to COVID cost loophole

Carmen Quintero works an early shift as a supervisor at a 3M distribution warehouse that ships N95 masks to a nation under siege from the coronavirus. On March 23, she had developed a severe cough, and her voice, usually quick and enthusiastic, was barely a whisper.

30 Jun 2020

Researchers perform first X-ray measurements on SARS-CoV-2 main protease

A team of researchers at the Department of Energy's Oak Ridge and Argonne national laboratories has performed the first room-temperature X-ray measurements on the SARS-CoV-2 main protease -- the enzyme that enables the virus to reproduce.

26 Jun 2020

SARS-CoV-2 has been evolving for at least 7 years

The burning question is how novel viruses acquire the ability to recognize, bind to and enter human cells for the first time – whether this is dependent only on viral proteins recognizing host cell proteins, or adaptations in other viral processes that allow replication in a human host.

25 Jun 2020

New method spurs production of antibiotic or antiparasitic compounds in actinobacteria

Researchers have developed a method to spur the production of new antibiotic or antiparasitic compounds hiding in the genomes of actinobacteria, which are the source of drugs such as actinomycin and streptomycin and are known to harbor other untapped chemical riches.

25 Jun 2020

New study explores post-COVID-19 inflammatory condition in children

In recent weeks, a multisystem hyperinflammatory condition has emerged in children in association with prior exposure or infection to SARS-CoV-2.

25 Jun 2020

Pixatimod is active in lab studies against SARS-CoV-2

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) circulating the world has caused over 9.6 million cases and over 490,000 deaths as of June 26, 2020. With neither an effective vaccine nor therapeutic drug yet available, intensive and widespread research is ongoing to develop a pharmacological intervention that will halt the global pandemic.

25 Jun 2020

Making AI systems to diagnose more like a doctor

Artificial intelligence (AI) is an important innovation in diagnostics, because it can quickly learn to recognize abnormalities that a doctor would also label as a disease.

24 Jun 2020

Effective neutralization of SARS-CoV-2 by synthetic nanobodies targeting the spike protein

In their recent bioRxiv paper, a multinational group of researchers reported rapid isolation and characterization of nanobodies from a synthetic library (known as sybodies) that target the receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein – with a strikingly high neutralization ability.

24 Jun 2020

New methods may contribute to future structure-based drug design

Many pharmaceuticals work by targeting what are known as "G-protein-coupled receptors". In a new study, scientists from Uppsala University describe how they have been able to predict how special molecules that can be used in new immunotherapy against cancer bind to these receptors.

24 Jun 2020

New therapy provides relief in patients with chronic low back pain

A new study has found that tanezumab, a monoclonal antibody that inhibits nerve activity, provides relief in patients with chronic low back pain, one of the leading reasons why people seek medical care and the number one cause of disability worldwide.

19 Jun 2020

Scientists aim to understand the biology of SARS-CoV-2 virus to enable drug development

The University of Huddersfield has awarded funding to a research team that aims to provide a head start in developing drugs that will combat future pandemics.

18 Jun 2020

Two clinical trials use low-dose X-rays to treat COVID-19 pneumonia

Previous studies have shown that low-dose, whole lung radiation in the form of X-rays can effectively treat severe pneumonia, with minimal side effects.

17 Jun 2020

New $26.9 million project aims to create better psychiatric drugs without side effects

Rapidly acting drugs to treat depression, anxiety, or substance abuse without side effects do not exist. Researchers led by Bryan L. Roth, MD, PhD, the Michael Hooker Distinguished Professor of Pharmacology at the UNC School of Medicine, are trying to change that.

16 Jun 2020

High-resolution 3D model reveals a link between Alzheimer's and diabetes

Pathological protein clumps are characteristic of a series of diseases, such as Alzheimer's disease, Parkinson's disease, and type 2 diabetes.

15 Jun 2020

Steroidal drugs subvert SARS-CoV-2 interaction with ACE2 receptors

A new study by Italian researchers and published online on the preprint server bioRxiv* in June 2020 reports the ability of several existing steroidal drugs to reduce the binding of the SARS-CoV-2 to the ACE2 receptor. This could help define newer strategies using viral entry blockers to reduce viral load.

14 Jun 2020

Early respiratory distress syndrome caused by SARS-CoV-2 in a newborn

A recent case report from the researchers at the University of São Paulo, published in the journal CLINICS, shows how newborns can also be infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and develop serious symptoms, even though the most likely route of infection in such cases is still not completely clear.

14 Jun 2020

Synthetic nanobodies potent neutralizers for SARS-CoV-2

Researchers at the Chinese Academy of Sciences report the generation of potent synthetic nanobodies that selectively and efficiently neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pseudovirus.

11 Jun 2020

UCD spin-out awarded €4.5 million funding to help combat coronavirus pandemic

SiriusXT (https://siriusxt.com/), a University College Dublin (UCD) spin-out company, has been awarded just over €4.5 million in blended (grant and equity) funding from the European Innovation Council Accelerator Pilot programme which is part of Horizon 2020, the EU's research and innovation programme.

11 Jun 2020

Protein design can solve the puzzle of Parkinson's disease

Dopamine is a neurotransmitter involved in everything from higher cognitive functions to motor control, motivation, arousal, reinforcement, and sexual gratification, the receptors it acts on have been a longstanding target for treating disorders like Parkinson's disease, which is caused by the degeneration of dopamine-using neurons that control movement.

11 Jun 2020